严重创伤、脓毒症和MODS免疫调理治疗的临床研究

Clinical study of immunoregulation therapy in the patients with severe trauma,sepsis or mods

目的:研究对严重创伤、脓毒症和MODS进行免疫调理治疗的可行性。方法:24例患者随机分成对照组(A)与治疗组(B),对照组常规治疗,治疗组常规治疗加胸腺肽α(迈普欣)和乌司他丁,疗程为7天,观察期28天。结果:治疗组CD14+单核细胞HLA-DR表达率治疗前后差异有统计学意义(P<0.05);并且TNF-α、IL-6、APACHEⅡ评分显著降低。结论:联用迈普新(胸腺肽α)和乌司他丁治疗严重脓毒症、MODS可显著降低TNF-α及IL-6的水平,可提高患者免疫力,改善患者的预后;对严重脓毒症、MODS采用免疫调理治疗具有可行性。

Objective：To study the feasibility of immunomodulation on the patients with severe trauma, sepsis or MODS. Methods ：24 patients were divided into control group （A） and therapy group （B） randomly. The control group was given routine therapy while the therapy group was treated with Ulinastatin and thymosin- α 1 for 7 days additionally, and two groups were observed for 28 days. Results ： Compared with the control group, the expression of CD14^＋ monocyte HLA-DR in the therapy group increased significantly, while the levels of TNF-α , IL-6 and APACHE H score in the therapy group decreased significantly.Conclusions ：Treating the patients with thymosin-α 1 and Ulinastatin could decrease the levels of TNF- α and IL-6, raise their immunity and improve their prognosis.Immunoregulation treatment is effective for patients with severe sepsis and MODS.